4-(2-methoxypyridin-3-yl)-3,6-dihydro-2H-pyridine-1-carboxylic acid

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 4-(2-methoxypyridin-3-yl)-3,6-dihydro-2H-pyridine-1-carboxylic acid
• 化学式: C₁₂H₁₄N₂O₃
• 分子量: 234.25
• InChiKey: HDUDUVHNEXVGMI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  62.7
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• BICYCLIC AZA COMPOUNDS AS MUSCARINIC RECEPTOR AGONISTS
  申请人：Heptares Therapeutics Limited

  公开号：EP3406609A1

  公开（公告）日：2018-11-28

  This invention relates to compounds that are agonists of the muscarinic M1 receptor and/or M4 receptor and which are useful in the treatment of muscarinic M1/M4 receptor mediated diseases. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds include those according to formula 1b or a salt thereof, wherein Q, R3 and R4 are as defined herein.

  本发明涉及的化合物是毒蕈碱 M1 受体和/或 M4 受体的激动剂，可用于治疗毒蕈碱 M1/M4 受体介导的疾病。本发明还提供了含有这些化合物的药物组合物以及这些化合物的治疗用途。化合物包括符合式 1b 的化合物 或其盐，其中 Q、R3 和 R4 如本文所定义。
• Bicyclic aza compounds as muscarinic M1 receptor and/or M4 receptor agonists
  申请人：Heptares Therapeutics Limited

  公开号：US10196380B2

  公开（公告）日：2019-02-05

  This invention relates to compounds that are agonists of the muscarinic M1 receptor and/or M4 receptor and which are useful in the treatment of muscarinic M1/M4 receptor mediated diseases. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds include those according to formula 1, or a salt thereof, wherein Q, R1, R2, R3 and R4 are as defined herein.

  本发明涉及的化合物是毒蕈碱 M1 受体和/或 M4 受体的激动剂，可用于治疗毒蕈碱 M1/M4 受体介导的疾病。本发明还提供了含有这些化合物的药物组合物以及这些化合物的治疗用途。化合物包括根据式 1 的化合物或其盐，其中 Q、R1、R2、R3 和 R4 如本文所定义。
• Bicyclic aza compounds as muscarnic M1 receptor and/or M4 receptor antagonists
  申请人：Heptares Therapeutics Limited

  公开号：US10385039B2

  公开（公告）日：2019-08-20

  This invention relates to compounds that are agonists of the muscarinic M1 receptor and/or M4 receptor and which are useful in the treatment of muscarinic M1/M4 receptor mediated diseases. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds include those according to formula 1, or a salt thereof wherein Q, R1, R2, R3 and R4 are as defined herein.

  本发明涉及的化合物是毒蕈碱 M1 受体和/或 M4 受体的激动剂，可用于治疗毒蕈碱 M1/M4 受体介导的疾病。本发明还提供了含有这些化合物的药物组合物以及这些化合物的治疗用途。化合物包括根据式 1 的化合物或其盐，其中 Q、R1、R2、R3 和 R4 如本文所定义。
• Bicyclic aza compounds as muscarinic M1 receptor and/or M4 receptor
  申请人：Heptares Therapeutics Limited

  公开号：US10689368B2

  公开（公告）日：2020-06-23

  This invention relates to compounds that are agonists of the muscarinic M1 receptor and/or M4 receptor and which are useful in the treatment of muscarinic M1/M4 receptor mediated diseases. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds include those according to formula 1, or a salt thereof, wherein Q, R1, R2, R3 and R4 are as defined herein.

  本发明涉及的化合物是毒蕈碱 M1 受体和/或 M4 受体的激动剂，可用于治疗毒蕈碱 M1/M4 受体介导的疾病。本发明还提供了含有这些化合物的药物组合物以及这些化合物的治疗用途。化合物包括根据式 1 的化合物或其盐，其中 Q、R1、R2、R3 和 R4 如本文所定义。
• Bicyclic AZA compounds as muscarinic M1 receptor and/or M4 receptor
  申请人：Heptares Therapeutics Limited

  公开号：US10961225B2

  公开（公告）日：2021-03-30

  This invention relates to compounds that are agonists of the muscarinic M1 receptor and/or M4 receptor and which are useful in the treatment of muscarinic M1/M4 receptor mediated diseases. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds include those according to formula 1, or a salt thereof, wherein Q, R1, R2, R3 and R4 are as defined herein.

  本发明涉及的化合物是毒蕈碱 M1 受体和/或 M4 受体的激动剂，可用于治疗毒蕈碱 M1/M4 受体介导的疾病。本发明还提供了含有这些化合物的药物组合物以及这些化合物的治疗用途。化合物包括根据式 1 的化合物或其盐，其中 Q、R1、R2、R3 和 R4 如本文所定义。